BARCELONA, Spain I August 19, 2023 I La Merie Publishing released its newest product reviewing the pipeline of fibroblast activation protein (FAP) targeted therapy and imaging candidates:
Fibroblast Activation Protein (FAP) Targeted Therapy & Companion Diagnostic Pipeline Review
Target: Fibroblast Activation Protein (FAP)
Product Category: Antibody; Protein; DNA; Radiopharmaceutical; Small Molecule
This product provides basic information on drug & imaging candidates in research and development targeting Fibroblast Activation Protein (FAP).
This product consists of:
- Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, territory of main competitor, indication(s) & R&D stage.
- Project History with links to source of information (press release, homepage, abstracts, presentations, annual reports etc).
- One-month online access to La Merie Publishing’s database for FAP-targeted drug & imaging candidates (prerequisite: access to internet).
This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.
Fibroblast activation protein (FAP) is selectively expressed in reactive stromal fibroblasts of epithelial cancers, granulation tissue of healing wounds, and malignant cells of bone and soft tissue sarcomas. This protein is thought to be involved in the control of fibroblast growth or epithelial-mesenchymal interactions during development, tissue repair, and epithelial carcinogenesis.
Targeting of FAP is well suited for tumor stroma delivery of effector moieties such as radioactive or cytotoxic payloads, stimulatory agonists, redirected cytotoxic T-cells, and cytokines/chemokines.
The report “Fibroblast Activation Protein (FAP) Targeted Therapy & Companion Diagnostic Pipeline Review” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/fibroblast-activation-protein-fap-targeted-therapy-companion-diagnostic-pipeline-review/
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.
La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest.
SOURCE: La Merie Publishing
Post Views: 400
BARCELONA, Spain I August 19, 2023 I La Merie Publishing released its newest product reviewing the pipeline of fibroblast activation protein (FAP) targeted therapy and imaging candidates:
Fibroblast Activation Protein (FAP) Targeted Therapy & Companion Diagnostic Pipeline Review
Target: Fibroblast Activation Protein (FAP)
Product Category: Antibody; Protein; DNA; Radiopharmaceutical; Small Molecule
This product provides basic information on drug & imaging candidates in research and development targeting Fibroblast Activation Protein (FAP).
This product consists of:
- Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, territory of main competitor, indication(s) & R&D stage.
- Project History with links to source of information (press release, homepage, abstracts, presentations, annual reports etc).
- One-month online access to La Merie Publishing’s database for FAP-targeted drug & imaging candidates (prerequisite: access to internet).
This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.
Fibroblast activation protein (FAP) is selectively expressed in reactive stromal fibroblasts of epithelial cancers, granulation tissue of healing wounds, and malignant cells of bone and soft tissue sarcomas. This protein is thought to be involved in the control of fibroblast growth or epithelial-mesenchymal interactions during development, tissue repair, and epithelial carcinogenesis.
Targeting of FAP is well suited for tumor stroma delivery of effector moieties such as radioactive or cytotoxic payloads, stimulatory agonists, redirected cytotoxic T-cells, and cytokines/chemokines.
The report “Fibroblast Activation Protein (FAP) Targeted Therapy & Companion Diagnostic Pipeline Review” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/fibroblast-activation-protein-fap-targeted-therapy-companion-diagnostic-pipeline-review/
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.
La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest.
SOURCE: La Merie Publishing
Post Views: 400
